circRNA-FOXK2基因作为靶标在制备或筛选乳腺癌治疗药物中的应用
By identifying and interfering with the circFOXK2 gene, we developed circRNA-FOXK2 gene inhibitors for the treatment of breast cancer. This addresses the shortcomings of existing breast cancer treatment methods, effectively inhibits the growth and migration of breast cancer cells, and provides new treatment ideas and directions.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHENZHEN NANSHAN DISTRICT PEOPLES HOSPITAL
- Filing Date
- 2023-11-10
- Publication Date
- 2026-07-17
AI Technical Summary
While there have been advances in existing breast cancer treatments, a deeper understanding of the molecular mechanisms of breast cancer and the development of effective treatments to reduce mortality are still needed. The circRNA-FOXK2 gene, as a novel breast cancer marker and therapeutic target, has high specificity and sensitivity and can regulate the growth and migration of breast cancer cells.
The circFOXK2 gene was identified through circular RNA sequencing analysis. Inhibitors of the circRNA-FOXK2 gene, such as siRNA, shRNA, ASO, and lentiviral vectors, were designed to interfere with circFOXK2 gene expression, block breast cancer cell growth and migration, and develop nucleic acid molecular drugs and lentiviral drugs for breast cancer treatment.
Significantly inhibiting the growth and migration of breast cancer cells, providing a new breast cancer treatment strategy, and improving treatment efficacy, circRNA-FOXK2 gene expression inhibitors have high specificity and sensitivity, and can block the growth and metastasis of breast cancer cells.
Smart Images
Figure CN117398466B_ABST